Stocks · News reference
Expanded the Company's strategic position in novel ADC payloads through a research collaboration on dual ADC payloads with Whitehawk Therapeutics to evaluate Akari's proprietary PH1 spliceosome modulating
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Akari Therapeutics announced that its Executive Director and Head of Oncology, Satyajit Mitra, will present the company's novel RNA-splicing antibody-drug conjugate (ADC) payload strategy at the upcoming 3rd Annual ADC Payload Summit.
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
Filed: 2026-10-01 AccNo: 0001493152-26-045364 Size: 289 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Akari Therapeutics reports positive preclinical data for AKTX-101 in urothelial cancer, showing efficacy in models resistant to current ADCs.